All
A Closer Look at Long-Term Outcomes in Young Cancer Survivors
July 10th 2018The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.
New Targeted Drugs Nearly Double Survival Time in Mantle Cell Lymphoma
July 5th 2018Since its classification in 1994, the prognosis for patients diagnosed with mantle cell lymphoma (MCL) was generally poor; however, survival rates have nearly doubled thanks to improvements in the treatment landscape over the past 10 years.
Cancer Rates 'Soar' in Flight Crew Compared with General Population
July 4th 2018While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.
Examining Early-Life Adversity and the 'Stress Hormone' in Ovarian Cancer Survivors
July 3rd 2018Adversity early on in life and increased stress levels could impact ovarian cancer outcomes – even if these instances happen before a woman is diagnosed, according to a recent article published in the journal Cancer.
Love the Genes You've Got, But Get Them Tested, Too
July 2nd 2018When my mom got cancer, the last thing on my mind was my own health, but she had the foresight and the care to get a genetic test so that her kids could live long and healthy lives. Today I am grateful for my mom, my whole family and the magic of science.
FDA Grants Priority Review to Frontline Keytruda Combination in Metastatic NSCLC
July 2nd 2018The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.